Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › REDEFINE 2

REDEFINE 2

CagriSema · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
CagriSema
Population
t2d
Official title
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Sponsor
Novo Nordisk A/S
Phase
3
Registry status
completed · 2023-02 → 2025-01
Participants
1206
Duration
68 weeks
Registry
NCT05394519

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
CagriSema 2.4/2.4 mgt2d681206−15.7 % vs −3.1 %
Δ −12.6 pp
−13.7 % vs −3.4 %
Δ −10.3 pp
−1.8 vs −0.48.4 vs 3.0———10.4 vs 12.9−6.5 vs −2.4verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (6)
  • CagriSema 2.4/2.4 mg · weight_tp · Results, Body Weight (p.652); also Table 2 row 'Percent chan
    For the treatment-policy estimand, the estimated mean change in body weight from baseline to week 68 (the first primary end point) was –13.7% with cagrilintide–semaglutide, as compared with –3.4% with placebo (estimated
  • CagriSema 2.4/2.4 mg · weight_eff · Results, Body Weight (p.652); Fig. 1B; full table in Table S
    For the trial-product estimand, the change in body weight was –15.7% with cagrilintide–semaglu- tide and –3.1% with placebo (estimated differ- ence, –12.6 percentage points; 95% CI, –13.4 to –11.7)
  • CagriSema 2.4/2.4 mg · hba1c · Results, Glycemic-Related End Points (p.654); Table 2 row 'C
    For the treatment-policy estimand, cagrilintide– semaglutide led to a greater mean reduction in the glycated hemoglobin level from baseline to week 68, as compared with placebo (–1.8 per- centage points vs. –0.4 percenta
  • CagriSema 2.4/2.4 mg · sbp · Table 2 (p.652), confirmatory secondary end point; also Resu
    Change in systolic blood pressure — mm Hg –6.5 –2.4 –4.1 (–6.0 to –2.1)
  • CagriSema 2.4/2.4 mg · ae_dc · Table 3 (p.656) row 'Leading to permanent discontinuation —
    Leading to permanent discontinuation Any adverse event 76 (8.4) 97 7.6 9 (3.0) 13 3.1
  • CagriSema 2.4/2.4 mg · sae · Table 3 (p.656) row 'Serious'; Results, Safety (p.655)
    Serious 94 (10.4) 138 10.8 39 (12.9) 51 12.1

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: REDEFINE 2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.